Galectin Therapeutics

Galectin Therapeutics is a biotechnology company focused on discovery and development, applying its work in galectin science and drug development to create new therapies for patients with chronic liver disease and cancer. Its drug candidates are based on carbohydrate technology targeting galectin proteins. The lead drug, belapectin (GR-MD-02), is a carbohydrate-based drug that inhibits the galectin-3 protein, and the lead development program is in MASH cirrhosis. Additional development programs are in severe atopic dermatitis, moderate-to-severe plaque psoriasis, and combination immunotherapy for advanced melanoma.

Galectin Therapeutics is a biotechnology company focused on discovery and development, applying leadership in galectin science and drug development to create new therapies for patients with chronic liver disease and cancer. Its drug candidates are based on carbohydrate technology targeting galectin proteins, which are described as key mediators of biologic and pathologic function. The company states that it leverages scientific and development expertise and relationships with outside sources to pursue cost-effective and efficient development, and that its strategy is to establish clinical development approaches that add value in the shortest time possible and to seek partners as programs advance and require greater resources. Its lead development program is in MASH with cirrhosis, with additional programs in severe atopic dermatitis, moderate-to-severe plaque psoriasis, and combination immunotherapy for advanced melanoma.

Biotechnology company focused on discovery and development of galectin-targeting therapies for chronic liver disease and cancer.

• Belapectin (GR-MD-02)

  A proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3, and it targets extracellular galectins. As a new chemical entity, belapectin is covered by patent protection through the year 2035.

1. 1Galectin Therapeuticsgalectintherapeutics.com
2. 2About Us – Galectin Therapeuticsgalectintherapeutics.com
3. 3About Belapectin – Galectin Therapeuticsgalectintherapeutics.com
4. 4About Galectin-3 – Galectin Therapeuticsgalectintherapeutics.com
5. 5Galectin Therapeutics (United States)wikidata.org